Table 1.

Clinical characteristics of the two pediatric patients with IgAN following COVID-19 vaccination

Patient no	Age, yrs	Sex	Variables	Before SARS-CoV-2 vaccination	Following SARS-CoV-2 vaccination
1	16	Male	Clinical symptoms	Microscopic hematuria	New-onset gross hematuria
			Serum creatinine, mg/dL	0.87	Day 6: 1.11 Day 20: 1.26 Day 55: 1.29 Day 100: 1.05
			Urine protein-to-creatinine ratio, g/g	0.03	Day 6: 0.28 Day 21: 0.35 Day 28: 0.31 Day 76–: 0.05〜0.10
			Oxford MEST-C score	M0E1S0T0C1	Day 24
			Treatment		Day 35 Start of steroid and immunosuppressive therapy
2	13	Female	Clinical symptoms	Microscopic hematuria	New-onset gross hematuria
			Serum creatinine, mg/dL	0.51	Day 12: 0.54
			Urine protein-to-creatinine ratio, g/g	0.08	Day 7: 1.99 Day 26: 0.11 Day 45–: 0.05–0.10
			Oxford MEST-C score	M0E0S0T0C0	Day 91
			Treatment		No treatment

IgAN, nephropathy; MEST-C, M = mesangial hypercellularity, E = endocapillary proliferation, S = segmental glomerulosclerosis, T = tubular atrophy/interstitial fibrosis, C = crescents